Chengtao Li
李成涛
elsewhere's corpus does not cover Chengtao Li as a subject. The retrieved material contains no chunks actually about this person — only name mentions in articles concerning other entities (e.g., a 2025 十字路口Crossing interview with Maozhu of Duozhuayu, and various 5Y Capital, 暗涌Waves, and Linear Capital pieces). No biographical facts, affiliations, or role descriptions for Chengtao Li appear in the bundle.
AI-generated — may contain errors, please verify.
Coverage
MaHui | Nearly 40 MaHui Members Named to 36Kr's X·36Under36 S-Class Young Entrepreneurs List
Medtech Entrepreneurship Is a "Game for the Brave": How to Sharpen Innovation, Product, and Organizational Capabilities | Ronghui
Discussing trends in medical technology innovation and upgrading R&D team organizational management.
Source Code Capital portfolio company Galixir announced the completion of a new funding round, with existing shareholder Source Code Capital continuing to increase its stake.
Continuously exploring the application of AI technology to empower innovative drug R&D
5Y News | Galixir Completes New Strategic Funding Round, Continues Advancing Drug R&D Pipeline
5Y Capital continues to watch for opportunities where information technology can be applied in healthcare and medicine.
5Y Talk | How Can Computing and AI Break Through the Traditional Paradigm of Drug Discovery?
Entering the Game, Direction, and the Future.
Rongbao · January | E-commerce and Retail Players Build Out Origin-Region Supply Chains; Multiple Chip, AI, and Enterprise Service Firms Close New Funding Rounds
Discover and accompany creators of a beautiful life.
Galixir's Chengtao Li: Using AI to Find the 'Key' to Curing Diseases in the Universe of Compounds | Ronghui
How artificial intelligence technology is accelerating drug discovery and development.
Galixir, a Source Code Capital portfolio company, raises tens of millions of dollars in funding, with existing investor Source Code Capital continuing to increase its stake
Galixir's technical capabilities are built on sophisticated AI models, enabling end-to-end coverage of drug discovery from hit compounds to preclinical candidates.
Galixir Announces Tens of Millions of Dollars in Funding, Using "AI+" to Break Through Bottlenecks in Drug Discovery
Gaorong Ventures led Galixir's angel round and continued to increase its stake in subsequent funding rounds.
5Y News | Galixir Announces Completion of Tens of Millions of USD in Funding, with Continued Backing from 5Y Capital
Breaking the Bottleneck in New Drug R&D with "AI+"
The Collision of AI and Pharmaceuticals: Galaxy Pharma Tech Raises Nearly $10 Million in Funding | Light Moments
Galixir announced the completion of a nearly $10 million Pre-A funding round. The round was co-led by Source Code Capital and DCM, with 5Y Capital participating as a follow-on investor. Gaorong Capital, the lead investor in the company's angel round, continued to increase its stake.
AI-assisted drug discovery company Galixir announced the completion of a Pre-A funding round of several million US dollars, co-led by Source Code Capital.
J&T Global Express has completed the development of drug discovery modules including retrosynthesis reaction prediction, drug screening, and molecular design.
